RAYDIAX, as a company that emerged from a #science #transfer from the Forschungscampus
STIMULATE / Otto-von-Guericke-Universität Magdeburg and is financed by private and
institutional investors, is a #sparring #partner for new start-up initiatives.
Dr. Thomas Hoffmann, CEO of RAYDIAX GmbH: "As a founding member of Business Angels Sachsen-Anhalt e.V., we are delighted to support future start-ups with the experience we have gained so far in science transfer. In particular, we believe it is important to help shape a lively association in Saxony-Anhalt that is committed to the region and gives young entrepreneurs the opportunity to turn their passion into reality."
We are happy to announce our newest long-term partnership together with the Forschungscampus
STIMULATE to deepen the clinical and technical. Together we will work on innovative research
topics relating to minimally invasive therapies.
Dr. Thomas Hoffmann, CEO and co-founder of RAYDIAX: "Joining the STIMULATE association ensures that our company maintains clinical and technical excellence at all times. The globally expanded network has supported us as a start-up in all matters since its foundation. We are pleased to institutionalize this by joining the association."
We are very pleased to announce that we have reached another milestone in the establishment
of our Therapy Assistance CT.
Dr. Thomas Hoffmann, CEO and co-founder of RAYDIAX: "We pursue the goal of sustainably strengthening cancer therapy through high-tech medical technology. Minimally invasive image-guided interventions offer numerous advantages for patients. With our targeted image-assistance system TACT, we are unleashing a completely new potential that will significantly expand the range of applications of these very gentle interventions, benefiting in particular patients for whom surgical cancer treatment appears to be too risky. With the closing of this financing round, we are in an optimal position to further develop our system in close coordination with our clinical partners, to accelerate market entry and to drive business growth."
Am 20.04. hatten wir die Gelegenheit gemeinsam mit dem Präsidenten des Leibniz-Instituts für
Wirtschaftsforschung Halle Prof. Dr. Reint Gropp, dem Rektor der
Otto-von-Guericke-Universität Magdeburg Prof. Dr.-Ing. Jens Strackeljan, sowie dem
Kulturmanager und Kunsthistoriker Prof. Christian Antz im Rahmen des Formats „#StreitBar“
über die Leistungs- und Innovationsfähigkeit von Hochschulen zu sprechen.
Die Schaffung interdisziplinärer Forschungsschwerpunkte durch gezielte, langfristige
Förderungen auf Universitäts-, Stadt-, Landes- und Bundesebene bilden die Grundlage. Die
konsequente Überführung dieser Ergebnisse in Produkte und das Erkennen und Fördern zum
Unternehmertum motivierter Talente müssen – innerhalb gebündelter Innovations- und
Transferräume in der Stadt – das Potenzial entfalten nationale und internationale Fachkräfte
zu erreichen. Nur so kann man als Startup in Zeiten zukünftiger Großansiedlungen (Intel) in
einem umkämpften Arbeitsmarkt bestehen.
Wir sind froh, dass die OvGU am Forschungscampus STIMULATE wichtiger Teil eines solchen
Schwerpunkts werden konnte.
Wir bedanken uns für die Möglichkeit der Diskussion!
Fotos: OVGU, Jana Dünnhaupt
Generating economic effects by translating research results into clinical application is the key to sustainable medical technology. To convince herself of this, the mayor of Magdeburg Simone Borris visited RAYDIAX today. Our goal is to further expand the excellent conditions the STIMULATE research campus offers young companies in Magdeburg. Together, we want to strengthen Magdeburg as a center for medical innovation.
As part of the STIMULATE research campus, we presented our science spin-off RAYDIAX to
German chancellor Olaf Scholz yesterday. In the conversation, we had the opportunity to
explain insights into the technical development of our world's first therapy assistance CT
for cancer treatment. Further focus was also to talk about the successful process of
transferring university research results into a commercially operating medical technology
company. As a team of (former) scientists and students of OvGU, we
are able to follow this path with the help of outstanding funding programs from the BMBF
From our point of view, the Chancellor's visit to the STIMULATE research campus in Magdeburg demonstrates the outstanding visibility that has been established in the field of MedicalEngineering in recent years. We are proud and excited to be a part of Magdeburg's continued development into a globally visible medical technology center that will sustainably improve medical care with technical and clinical innovations.
Last week we were part of the STIMULATE Retreat to create innovative ideas, concepts and
technologies to further improve the outcome of minimally invasive therapies for patients and
caregivers in the future!
Clinicians from different departments pitched their experiences and challenges in their daily work with minimally invasive therapies. In different sessions we brainstormed innovative solutions with miscellaneous partners.
Together with this excellent network with clinicians, industrial partners and researchers we benefit to making minimally invasive therapies better for everyone!
This week we followed the invitation from the Weinberg Campus Accelerator to their Startup
Meetup event in Halle. We were delighted to connect with young startups, experienced
founders and investors. Thank you for the interesting meet-up and the great event!
Yesterday we had the great opportunity to represent RAYDIAX at the CampusPitch and to meet many motivated students. We shared our vision and informed the students about jobs and opportunities at RAYDIAX. We are looking forward to find new team members, who would like to develop the world’s first TACT with us!
With the foundation of “RAYDIAX GmbH” we have reached another milestone. Over
the next few
years, we will build up the company to develop and launch the world's first
RAYDIAX aim is to assist physicians by enabling safe, intuitive and efficient interventional procedures. In this way, we will support the clinical establishment of minimally invasive therapy procedures and improve patient outcomes.
We also want to thank our partners and supporters! We look forward to the next exciting years!
Yesterday we had the excellent opportunity to present our company to leading investors as
one of the 11 selected startups out of more than 150 applications at the MedTech Pitch
Many thanks for the organization to the team of the High-Tech Gründerfonds!
We are looking forward to the follow ups with interested investors for the successful completion of our funding round.
Also, a thank you to the Bundesministerium für Wirtschaft und Klimaschutz, the Forschungscampus STIMULATE, and Otto-von-Guericke-Universität Magdeburg for making it all possible.
It is time to say thank you for an eventful and turbulent year. We are pleased to have been
able to start building our RAYDIAX company in 2021 to advance global cancer treatment with
our TACT system. A particular “Thank You” goes to the German Federal Ministry of Economics
Climate Action for making our first round of funding possible!
In addition, we are very pleased that our clinical and technical partners have always been
there with their expertise to support us on this new path.
We wish you all a merry Christmas season, relaxing holidays and a healthy and successful year 2022. We look forward to our continued collaboration!
See you in 2022.
We visited the EXIST 'Gründergespräch' to get experiences and knowledges about personell, recruiting and working law for startups.
RAYDIAX was present at RSNA in Chicago to get in touch with new partners.
We were at the EXIST-Seminar 'Gründerteam' in Berlin and get in touch with other EXIST founded startup teams.
Sneak Peak: Together with our clinical partner, we are evaluating the interaction concept of our TACT in virtual reality at the STIMULATE research campus.